Analyzing New England Nuclear (LNTH) and Trinity Biotech (TRIB)

New England Nuclear (NASDAQ: LNTH) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Risk and Volatility

New England Nuclear has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Valuation and Earnings

This table compares New England Nuclear and Trinity Biotech’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
New England Nuclear $331.38 million 1.65 $123.38 million $1.00 14.25
Trinity Biotech $99.14 million 0.97 -$40.27 million $0.26 17.69

New England Nuclear has higher revenue and earnings than Trinity Biotech. New England Nuclear is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

90.0% of New England Nuclear shares are held by institutional investors. Comparatively, 70.4% of Trinity Biotech shares are held by institutional investors. 1.2% of New England Nuclear shares are held by insiders. Comparatively, 12.7% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares New England Nuclear and Trinity Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
New England Nuclear 38.32% -145.14% 11.84%
Trinity Biotech -41.38% 3.26% 1.28%

Analyst Recommendations

This is a summary of current recommendations for New England Nuclear and Trinity Biotech, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
New England Nuclear 0 1 3 0 2.75
Trinity Biotech 0 0 0 0 N/A

New England Nuclear presently has a consensus price target of $24.00, indicating a potential upside of 68.42%. Given New England Nuclear’s higher possible upside, analysts clearly believe New England Nuclear is more favorable than Trinity Biotech.

Summary

New England Nuclear beats Trinity Biotech on 10 of the 13 factors compared between the two stocks.

New England Nuclear Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. Further, it offers Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile, and Uni-Gold Syphilis products. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Receive News & Ratings for New England Nuclear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for New England Nuclear and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply